Bolden Therapeutics
Biotechnology ResearchView the employees at
Bolden Therapeutics-
Dayshalis Ofray Research Scientist at Bolden Therapeutics
-
Boston, Massachusetts, United States
-
Rising Star
Anne Valat Director of Research at Bolden Therapeutics-
Cambridge
-
Rising Star
Julia K. Hecking Associate Scientist at Bolden Therapeutics-
Boston, Massachusetts, United States
-
Rising Star
Julia K. Hecking Biotechnology Graduate Student at Brown University & Research Co-op at Bolden Therapeutics-
Rising Star
Johnny Page Co-Founder and CEO at Bolden Therapeutics | MD Candidate at Alpert Medical School-
Providence, Rhode Island, United States
-
Rising Star
Overview
Bolden Therapeutics is a biotechnology company developing first-in-class therapeutics to treat central nervous system diseases such as Alzheimer’s and ischemic stroke. The company’s scientific founders have identified a key molecular pathway to stimulate neural stem cells to promote the birth of new neurons (neurogenesis) in the adult brain. In a proprietary mouse model Bolden has established a proof-of-concept of this approach to increase neurogenesis and enhance hippocampal-dependent memory. The company is actively developing antisense oligonucleotide and monoclonal antibody therapeutics to modulate this pathway.
-